RedHill Says Bekinda Looks Best In IBS-D, Despite Mixed Phase II Data
Executive Summary
Company eyes a slice of market for diarrhea-predominant irritable bowel syndrome, a growing space in recent years with the entry of new products.
You may also be interested in...
Tackling Acute Gastroenteritis: RedHill Biopharma's Bekinda A Novel Approach?
A new long-acting ondansetron product that reduces nausea and vomiting during acute viral gastroenteritis, whatever the type of virus involved and for long periods of time, could change the way emergency physicians respond to gastroenteritis outbreaks, and is underpinning the specialty pharma business strategy of RedHill Biopharma.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.